Detalles de la búsqueda
1.
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis.
Br J Cancer
; 130(2): 269-274, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38030749
2.
Cardiovascular magnetic resonance characterization of myocardial tissue injury in a miniature swine model of cancer therapy-related cardiovascular toxicity.
J Cardiovasc Magn Reson
; 26(1): 101033, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38460840
3.
The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations.
Hered Cancer Clin Pract
; 22(1): 7, 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38741145
4.
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
Int J Cancer
; 153(4): 803-814, 2023 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36971103
5.
The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
Cancer
; 129(6): 901-907, 2023 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36571512
6.
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
Oncologist
; 28(7): 565-574, 2023 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37210568
7.
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
Breast Cancer Res Treat
; 201(2): 257-264, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432545
8.
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Breast Cancer Res Treat
; 202(1): 191-201, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37589839
9.
Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant.
J Clin Gastroenterol
; 57(3): 317-323, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35220378
10.
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis.
Breast Cancer Res Treat
; 194(3): 597-606, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35715538
11.
Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.
Genet Med
; 24(3): 564-575, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34906490
12.
The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT.
Clin Genet
; 101(3): 317-323, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34897671
13.
Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study.
J Gen Intern Med
; 37(8): 1862-1869, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34173196
14.
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Gynecol Oncol
; 164(3): 514-521, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35063280
15.
Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.
Cancer
; 127(6): 828-833, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33146899
16.
Survival from breast cancer in women with a BRCA2 mutation by treatment.
Br J Cancer
; 124(9): 1524-1532, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33597716
17.
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat
; 187(2): 515-523, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33423179
18.
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
Breast Cancer Res Treat
; 189(2): 411-423, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34302589
19.
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
Breast Cancer Res Treat
; 189(3): 641-651, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34417675
20.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34120223